Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Surg Oncol ; 19(3): 1034-42, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21989664

ABSTRACT

BACKGROUND: The primary objectives of this work are to (1) quantitate tumor burden in sentinel lymph nodes (SLNs), and (2) assess the independent contributions of SLN tumor burden and primary melanoma thickness (PMT) with respect to progression-free survival (PFS) and overall survival (OS). METHODS: Sixty-three patients (41 male and 22 female) with one or more positive SLNs were available for review in this study, with median follow-up of 6.8 years. PMT was measured and SLN metastases were assessed for size, as maximum metastasis size (MMS) in mm, by hematoxylin and eosin (H&E) and immunohistochemistry (S100 and HMB45). PFS and OS were calculated from time of SLN resection until melanoma recurrence or death. Univariate and multivariate analyses and trend test were performed. RESULTS: Kaplan-Meier estimates of PFS and OS differed significantly by MMS (log-rank P = 0.031 for PFS and P = 0.016 for OS) and PMT (log-rank P = 0.036 for PFS and P < 0.001 for OS). After adjusting for age and gender, the hazard ratio (HR) associated with MMS was 1.09 per mm increase (P = 0.05) for PFS, and 6.30 (P = 0.014) and 5.41 (P = 0.048) for OS in patients, respectively, with MMS of 0.6-5.5 mm and MMS ≥5.5 mm compared with those with MMS <0.6 mm. When patients were stratified by their tumor characteristics of PMT, the risk for disease progression and worse OS was substantially higher for the group with PMT ≥ 4.5 mm (HR = 13.10 and P = 0.022 for PFS; HR = 17.26 and P < 0.001 for OS) relative to the baseline group with PMT <1.6 mm. All patients had completion lymph node dissection (CLND) except for four patients. Patients with positive CLND (14, 22.2%) showed significant worse PFS (P = 0.002) and OS (P = 0.0003) than the negative CLND group (45, 71.4%). CONCLUSIONS: PMT and MMS were independently prognostic of PFS and OS in melanoma patients. Patients with negative CLND had significantly better PFS and OS than those with positive CLND.


Subject(s)
Lymph Nodes/pathology , Melanoma/pathology , Sentinel Lymph Node Biopsy , Skin Neoplasms/pathology , Female , Humans , Lymphatic Metastasis , Male , Melanoma/mortality , Skin Neoplasms/mortality , Survival Rate
2.
Ann Surg Oncol ; 18(10): 2919-24, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21468784

ABSTRACT

BACKGROUND: Determining how many sentinel lymph nodes (SLNs) should be removed for melanoma is important. The purpose of this study is to determine the frequency at which nodes that are less radioactive than the "hottest" node (which is negative) are positive for melanoma, how low of a radioactivity should warrant harvest, and if isosulfan blue is necessary. METHODS: We reviewed 1,152 melanoma patients who underwent lymphoscintigraphy with technetium, with or without blue dye, and SLN dissection from 1996 to 2008. SLNs with radioactivity ≥10% of the "hottest" SLN, all blue nodes, and all suspicious nodes were removed and analyzed. The miss rate was calculated as the proportion of node positive cases in which the "hottest" SLN was negative. RESULTS: SLNs were identified in 1,520 nodal basins in 1,152 patients. SLN micrometastases were detected in 218 basins (14%) in 204 patients (18%). In 16% of SLN-positive patients (33/204 patients), the positive SLN was found to have a lower radioactive count than the "hottest" SLN, which was negative. In 21 of these cases, the positive SLNs had radioactivity ≤50% of the "hottest" SLN. The 10% rule significantly reduced the miss rate to 2.5% compared with removal of only the "hottest" SLN (miss rate = 16%). Also, blue dye did not significantly decrease the miss rate compared with radiocolloid alone using the 10% rule. CONCLUSIONS: To decrease the miss rate, all SLNs with ≥10% of the ex vivo radioactivity of the "hottest" SLN should be removed and blue dye is not essential.


Subject(s)
Melanoma/diagnostic imaging , Melanoma/pathology , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/secondary , Adolescent , Adult , Aged , Aged, 80 and over , Coloring Agents , False Negative Reactions , Female , Follow-Up Studies , Humans , Lymph Node Excision , Lymphatic Metastasis , Lymphoscintigraphy , Male , Melanoma/surgery , Middle Aged , Neoplasm Micrometastasis , Prognosis , Radiopharmaceuticals , Retrospective Studies , Rosaniline Dyes , Sentinel Lymph Node Biopsy , Skin Neoplasms/surgery , Technetium Tc 99m Sulfur Colloid , Young Adult
3.
J Immunother ; 32(6): 632-7, 2009.
Article in English | MEDLINE | ID: mdl-19483646

ABSTRACT

A hypothesis generating study was conducted to evaluate the safety and efficacy of prolonged (3 y) administration of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) as surgical adjuvant therapy in patients with melanoma at high risk of recurrence. Ninety-eight evaluable patients with stages II(T4), III, or IV melanoma were given prolonged treatment with GM-CSF after surgical resection of disease. The GM-CSF was administered subcutaneously in 28-day cycles, such that a dose of 125 microg/m2 was delivered daily for 14 days followed by 14 days rest. Treatment cycles continued for 3 years or until disease recurrence, which could not be surgically excised. Patients were evaluated for toxicity, disease-free survival, and melanoma-specific survival. Prolonged administration of GM-CSF was well tolerated; grade 1 or 2 side effects occurred in 82% of the patients. There were no grade 3 or 4 treatment-related side effects. Two patients developed acute myelogenous leukemia after completion of 3 years of GM-CSF administration. With a median follow-up of 5.3 years, the median melanoma-specific survival has not yet been reached. The 5-year melanoma-specific survival rate was 60%. The current study has expanded the preliminary evidence on GM-CSF as adjuvant therapy of patients with melanoma who are at high risk for recurrence.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage , Melanoma/drug therapy , Neoplasm Recurrence, Local/prevention & control , Skin Neoplasms/drug therapy , Adjuvants, Immunologic/adverse effects , Aged , Cancer Vaccines/therapeutic use , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Female , Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects , Humans , Kaplan-Meier Estimate , Male , Melanoma/pathology , Melanoma/surgery , Middle Aged , Neoplasm Staging , Recombinant Proteins , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Survival Rate
5.
World J Surg ; 29(6): 683-91, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15895193

ABSTRACT

Selective sentinel lymphadenectomy (SSL) following preoperative lymphoscintigraphy is the most significant recent advance in the management of patients with primary melanoma. This study evaluates the prognostic value of sentinel lymph node (SLN) status and other risk factors in predicting survival and recurrence in patients with primary cutaneous melanoma. From October 1993 to July 1998 a series of 412 patients with primary invasive melanoma underwent SSL at the UCSF/ Mt. Zion Melanoma Center. The outcome of 363 evaluable patients is summarized in this study. The factors related to survival and disease recurrence were analyzed by Cox proportional hazard regression models. The overall incidence of patients with positive SLNs was 18%. Over a median follow-up of 4.8 years, the overall mortality rate in patients with primary cutaneous melanoma was 18.7%, and 74 recurrences occurred (20.4%). Mortality was significantly related to SLN status [HR = 2.06; 95% Confidence interval (CI) 1.18, 3.58], angiolymphatic invasion (HR = 2.21; 95% CI 1.08, 4.55), ulceration (HR = 1.79; 95% CI 1.02, 3.15), mitotic index (HR =1.38; 95% CI 1.01, 1.90), and tumor thickness (HR = 2.20, 95% CI 1.21, 3.99). Factors significantly related to disease-free survival included SLN status (HR = 2.09; 95% CI 1.31, 3.34), tumor thickness (HR = 1.89; 95%. CI 1.20,2.98), and age (HR= 1.26 95% CI 1.08, 1.47). SLN status was the most significant factor for melanoma recurrence and death. Other important predictors include tumor thickness, ulceration, lymphatic invasion, and mitotic index.


Subject(s)
Melanoma/mortality , Melanoma/secondary , Neoplasm Recurrence, Local/etiology , Neoplasm Recurrence, Local/mortality , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Adult , Aged , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Male , Melanoma/surgery , Middle Aged , Prognosis , Risk Factors , Sentinel Lymph Node Biopsy , Skin Neoplasms/surgery , Survival Rate , Time Factors
6.
Proc Natl Acad Sci U S A ; 102(17): 6092-7, 2005 Apr 26.
Article in English | MEDLINE | ID: mdl-15833814

ABSTRACT

Because of the paucity of available tissue, little information has previously been available regarding the gene expression profiles of primary melanomas. To understand the molecular basis of melanoma progression, we compared the gene expression profiles of a series of nevi, primary melanomas, and melanoma metastases. We found that metastatic melanomas exhibit two dichotomous patterns of gene expression, which unexpectedly reflect gene expression differences already apparent in comparing laser-capture microdissected radial and vertical phases of a large primary melanoma. Unsupervised hierarchical clustering accurately separated nevi and primary melanomas. Multiclass significance analysis of microarrays comparing normal skin, nevi, primary melanomas, and the two types of metastatic melanoma identified 2,602 transcripts that significantly correlated with sample class. These results suggest that melanoma pathogenesis can be understood as a series of distinct molecular events. The gene expression signatures identified here provide the basis for developing new diagnostics and targeting therapies for patients with malignant melanoma.


Subject(s)
Gene Expression Profiling , Melanoma/genetics , Nevus/genetics , Biopsy , Disease Progression , Humans , Immunohistochemistry , Melanoma/pathology , Mutation , Neoplasm Metastasis/genetics , Nevus/pathology , Oligonucleotide Array Sequence Analysis , Proto-Oncogene Proteins B-raf/genetics , RNA, Neoplasm/genetics , RNA, Neoplasm/isolation & purification
7.
Clin Nucl Med ; 30(3): 150-8, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15722817

ABSTRACT

UNLABELLED: We want to define the patterns of lymphatic drainage for primary melanoma to sentinel lymph nodes (SLNs) based on a large lymphoscintigraphic database. Preoperative lymphoscintigraphy was used to identify and classify SLN drainage basins and patterns of drainage. METHODS: Lymphoscintigraphy using intradermally administered technetium-99m labeled sulfur colloid was performed on 400 consecutive patients with malignant melanoma to define lymphatic drainage channels and draining SLN basins before surgery. Primary tumor sites consisted of head and neck, upper extremity, trunk, and lower extremity. Different types of drainage patterns were classified and correlated with different anatomic sites. RESULTS: SLN(s) were identified in over 98% of the patients, whereas lymphatic drainage channels were successfully identified in 90% of the patients. Drainage from the primary site to a single SLN through a single lymphatic channel (type IA) was seen in 186 of 400 patients (47%) as the most common type. In patients with a single SLN within a single basin (type I-V), the percentage of patients with primary lesions in the head and neck, upper extremity, trunk, and lower extremity regions were 61%, 79%, 55%, and 78%, respectively. In cases of multiple lymphatic channels (type VI-VII), the percentages of patients with primary lesions in the head and neck, upper extremity, trunk, and lower extremity regions were 24%, 8%, 36%, and 19%, respectively. CONCLUSION: Various drainage patterns were noted from primary melanomas in different anatomic sites. Preoperative lymphoscintigraphy is important in establishing the SLN basins for harvesting the SLN(s).


Subject(s)
Lymph Nodes/diagnostic imaging , Lymph Nodes/metabolism , Lymphatic Metastasis/diagnostic imaging , Melanoma/diagnostic imaging , Melanoma/secondary , Sentinel Lymph Node Biopsy/methods , Technetium Tc 99m Sulfur Colloid/pharmacokinetics , Humans , Lymph Node Excision , Lymph Nodes/pathology , Lymph Nodes/surgery , Lymphatic Metastasis/pathology , Melanoma/classification , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics
8.
Ann Surg Oncol ; 10(2): 196-200, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12620917

ABSTRACT

BACKGROUND: Harvesting the sentinel lymph node (SLN) is important in the management of patients with primary cutaneous melanoma. Selective sentinel lymphadenectomy (SSL) is generally performed at the time of wide local excision (WLE). The aim of our study was to determine whether delayed SSL is useful in detecting micrometastasis to the regional basin in patients with previous WLE of an extremity melanoma. METHODS: Of 203 patients with a primary melanoma site located on the upper or lower extremity seen at the University of California, San Francisco/Mount Zion Melanoma Center from May 17, 1994, to March 23, 1999, 24 patients had a WLE of their extremity melanoma with adequate margins before referral. SSL was performed to assess micrometastasis in the regional lymph node basin after preoperative lymphoscintigraphy. RESULTS: At least 1 SLN was identified in all 24 patients. At a median follow-up of 3 years, two patients showed micrometastasis in the SLNs. One of these two patients developed recurrence, and all remaining patients showed no evidence of disease. CONCLUSIONS: Although it is generally advised that WLE should be performed simultaneously with SSL, delayed SSL after WLE of an extremity melanoma can still provide valuable staging information, which is critical for management of the patient.


Subject(s)
Extremities/pathology , Lymph Node Excision , Lymphatic Metastasis/pathology , Melanoma/pathology , Skin Neoplasms/pathology , Adult , Aged , Female , Humans , Male , Melanoma/surgery , Middle Aged , Neoplasm Staging , Sentinel Lymph Node Biopsy , Skin Neoplasms/surgery
9.
Surg Technol Int ; I: 306-307, 1991 Nov.
Article in English | MEDLINE | ID: mdl-28581577

ABSTRACT

Regional perfusion of cancer resulted from studies that infused nitrogen mustard into arteries supplying tumours while at the same time blocking the venous return to maximise exposure of the tumour to the chemotherapeutic agent.

SELECTION OF CITATIONS
SEARCH DETAIL
...